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Abstract
Previously, we found that distinct brain areas predict individual selection bias in decisions between
small immediate (“Now”) and larger delayed rewards (“Later”). Furthermore, such selection bias
can be manipulated by endogenous opioid blockade. To test whether blocking endogenous opioids
with Naltrexone (NTX) alters brain activity during decision-making in areas predicting individual
bias, we compared fMRI BOLD signal correlated with Now versus Later decision-making after acute
administration of NTX (50 mg) or placebo. We tested abstinent alcoholics and control subjects in a
double-blind two-session design. We defined regions of interest (ROI) centered on activation peaks
predicting Now versus Later selection bias. NTX administration significantly increased BOLD signal
during decision-making in the right lateral orbital gyrus ROI, an area where enhanced activity during
decision-making predicts Later bias. Exploratory analyses identified additional loci where BOLD
signal during decision-making was enhanced (left orbitofrontal cortex, left inferior temporal gyrus,
and cerebellum) or reduced (right superior temporal pole) by NTX. Additional analyses identified
sites, including the right lateral orbital gyrus, in which NTX effects on BOLD signal predicted NTX
effects on selection bias. These data agree with opioid receptor expression in human frontal and
temporal cortices, and suggest possible mechanisms of NTX’s therapeutic effects.
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1. Introduction
The non-selective opioid antagonist naltrexone (NTX) is one of few drugs with U.S. Food and
Drug Administration (FDA) approval for the treatment of alcoholism. NTX is also used to treat
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other substance addictions and impulse-control disorders. NTX reduces ethanol consumption
in subjects with a history of alcohol abuse (Anton et al., 1999; Davidson et al., 1999;
Heidbreder, 2005; Hernandez-Avila et al., 2006; O’Brien et al., 1996), and in animals trained
to self-administer ethanol (Boyle et al., 1998; Stromberg et al., 1998). Moreover, NTX reduces
drug-seeking behavior triggered by drug-cue exposure in animal models (Ciccocioppo et al.,
2003; Ciccocioppo et al., 2002; Liu and Weiss, 2002) and alcohol-cue induced craving in
human alcoholics (Monti et al., 1999; O’Malley et al., 2002; Rohsenow et al., 2000). However,
the mechanisms of these clinically important actions of NTX are not well understood. NTX
has highest affinity for μ-opioid receptors, but substantial affinity for κ- and δ-opioid receptors
(Kreek, 1996). Through its modulation of the endogenous opioids that control midbrain
dopaminergic neurons, NTX alters forebrain release of dopamine (DA) (Herz, 1995; Margolis
et al., 2006; Spanagel et al., 1992). Through blocking opioid disinhibition of ventral tegmental
area (VTA) neurons, NTX reduces ethanol-induced release of DA in the nucleus accumbens
(Altshuler et al., 1980; Harris and Erickson, 1979), which contributes to the motivation to
consume alcohol. Based on this neurobiological action of NTX, candidate mechanisms for its
therapeutic action in alcoholics include an attenuation of the rewarding effects of alcohol, for
which there is experimental support (Sinclair, 2001; Swift et al., 1994; Volpicelli et al.,
1995). There is also evidence that NTX can increase the aversive effects of ethanol (Davidson
et al., 1999; de Wit et al., 1999; McCaul et al., 2000; Mitchell et al., 2005a). However, NTX
can also significantly reduce alcohol craving in alcoholics during abstinence (Monti et al.,
1999; O’Malley et al., 2002; Rohsenow et al., 2000), and attenuate thoughts and behaviors
associated with drinking (Anton et al., 1999). Thus, NTX may act, in part, via alteration of
specific cognitive processes. One possibility that has received experimental support is that
NTX reduces the tendency to choose impulsively (Kieres et al., 2004; Mitchell et al., 2007;
O’Malley et al., 2002). In fact, NTX relieves a wide variety of impulse control disorders (Grant,
2005; Kim et al., 2001; Marrazzi et al., 1995; Raymond et al., 2002; Symons et al., 2004).
These data all suggest that endogenous opioids promote impulsivity, and that blocking
endogenous opioid activity with NTX reduces impulsiveness.
To address whether NTX alters brain activity in regions known to predict individual bias toward
immediate rewards, we used a NTX challenge in the context of functional magnetic resonance
imaging (fMRI) while human subjects performed a modified delay discounting (DD) task. In
a previous fMRI study of this task (Boettiger et al., 2007), we found that distinct brain areas
predict individual selection bias. These areas include the dorsal prefrontal cortex, the posterior
parietal cortex, the orbitofrontal cortex (OFC), the parahippocampal gyrus adjacent to the
amygdala, the posterior cerebellum, and the inferior and middle temporal gyri. The task is
comprised of numerous trials in which subjects are instructed to choose between two amounts
of money, a smaller amount available “Now” (e.g. “$80 TODAY”) or a larger amount available
“Later” (e.g. “$100 in 1 Month”; Figure 1). We have quantified individual selection bias in
this task as an “Impulsive Choice Ratio” (ICR) (Mitchell et al., 2005b). In a previous
pharmacology study, we found that such selection bias can be manipulated by endogenous
opioid blockade (Mitchell et al., 2007). To test the hypothesis that blocking endogenous opioid
signaling with NTX would alter regional brain activity that predicts individual selection bias
during decision-making, we compared the fMRI BOLD signal correlated with Now versus
Later decision-making after acute administration of NTX (50 mg) or placebo. Subjects were
either abstinent alcoholics or control subjects with no history of substance abuse, and they were
tested in a double-blind randomized two-session crossover design.
For the purpose of analyzing brain activity between sessions, we defined regions of interest
(ROI) as 10mm spheres centered on activation peaks that predict Now vs. Later selection bias
(Boettiger et al., 2007), comparing the BOLD signal during decision-making within these ROI
between NTX and placebo sessions. We also conducted exploratory mapwise analyses to
identify other brain areas in which BOLD signal during decision-making was enhanced or
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reduced by NTX administration. Finally, given the widespread evidence for variability in NTX
response, we conducted additional analyses to identify sites in which NTX effects on BOLD
signal predicted NTX effects on selection bias.
NTX is not effective in treating all alcoholics, thus, determining the moderators of NTX’s
effects is a critical goal of current research. Investigation of genetic moderators has of NTX’s
effects have largely focused on the A118G (ASP40) variant of the μ–opioid receptor gene
(OPRM1). This OPRM1 variant produces a μ-opioid receptor with greater affinity for β-
endorphin (Bond et al., 1998), suggesting a gain-of-function effect. However, more recent data
indicate that the ASP40 variant impairs transcription and thus expression of the receptor
protein, resulting in a loss-of-function effect (Zhang et al., 2005). Laboratory studies
demonstrate that this OPRM1 variant determines NTX’s effect on physiological responses to
alcohol cue exposure (McGeary et al., 2006) and to alcohol-induced high (Ray and Hutchison,
2007). Moreover, clinical trials have yielded some data demonstrating that that the ASP40
variant predicts therapeutic response to NTX (Anton et al., 2008; Oslin et al., 2003); although,
other studies have failed to replicate this finding (Gelernter et al., 2007). Thus, we also collected
genetic material from these subjects to test whether the A118G variant of the OPRM1 gene
also modulates NTX effects on immediate reward bias or underlying neural circuit activity. In
addition to the A118G variant of the OPRM1 gene, we also tested several other single




Participants were either abstinent alcoholics (AA; n = 9) or control subjects with no history of
substance abuse (CS; n = 10). All participants were healthy, right-handed volunteers (8 females;
mean age: 28.3 ± 5.8), and were paid for their participation. Participants were screened for
psychoactive drug use (Biotechnostix, Inc.), including alcohol (Lifeloc Technologies, Inc.) at
the start of each session. Five additional participants were tested, but were excluded from fMRI
analyses due to excess head motion or equipment failure. All subjects had at least a high school
education, and the two groups did not differ in terms of socio-economic status, age, IQ, and
years of education. Alcohol addiction severity (prior to sobriety for AA group) was assessed
via the Alcohol Use Disorders Identification Test (AUDIT; (Saunders et al., 1993)), with mean
AUDIT scores of 19 ± 7 and 5 ± 2, for the AA and CS groups, respectively (scores ≥ 8 indicate
problem drinking). AA subjects self-reported a minimum of 2 weeks sobriety at the time of
recruitment (mean sobriety = 2.5 yrs). All participants gave written, informed consent, in
accordance with the guidelines of the University of California, Berkeley Committee for the
Protection of Human Subjects. Subject payment was not dependent upon choice behavior in
the task.
2.2. Experimental paradigm
Each subject completed two sessions separated by a minimum of 48 h. At the start of each
session, subjects gave written, informed consent and after completing screening for
contraindications for NTX, subjects were administered either a 50mg NTX capsule or an
identical placebo capsule. Experimenter and subject were blind to capsule content; capsule
order was counter-balanced across subjects. Three hours after pill ingestion, subjects performed
a delay discounting task in the context of an fMRI scanning session. For the task, subjects made
a series of choices between Now and Later hypothetical monetary rewards. Later amounts were
$2, $5, $10, $20, or $100, at 1 of 5 future delays: 1 WEEK, 2 WEEKS, 1 MONTH, 3 MONTHS,
or 6 MONTHS. The Now option was always a lesser amount available TODAY. Now and
Later options randomly appeared on the right or left side. Subjects were given task instructions
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and a brief practice session to familiarize them with the delay discounting (DD) task. Subjects
performed the DD task within an fMRI scanner, while we collected continuous whole-brain
bold oxygen level dependent (BOLD) signal. Scanning comprised 8 functional scans of 37
trials each (32 choice trials, and 5 “null” trials); trial type order was pseudorandom and unique
for each subject (total scanning duration ~1 hour). For each trial, subjects were shown a cue
that indicated how to select between the two subsequently displayed hypothetical reward
options, each option was a dollar amount available at a point in time (Figure 1); these two
alternatives are considered as “Now” and “Later”. The Now option was available “TODAY”
and was the lesser of the two amounts by a percentage randomly selected from the set: {30%,
15%, 10%, 5%}. Right-left position of each option was randomized across trials. Subjects
indicated their choice by pressing a button on an MRI-compatible keypad. Instruction cues
included: WANT (W), DON’T WANT (DW), SOONER, and LARGER, the latter two cues
are considered together as “CONTROL” (CON). In the W condition, subjects chose their
preferred option. In the DW condition, subjects were asked to make the same evaluation and
press the button corresponding to the opposite choice. On CON trials, subjects selected the
option reflecting either the sooner time point or larger amount of money, depending on the
instruction cue. CON trial performance verified subject comprehension and compliance with
task instructions. The DW condition provides a gross assessment of motor impulsiveness, by
comparing inferred choices in the DW trials as a function of time with choices in the W
condition as a function of time. This comparison rules out spurious impulsive choice as a result
of unintended motor responses. Trial types frequencies were weighted with ratios of 1/2 for
the W condition and 1/6 each for each of the other conditions. The order of inter-trial intervals
was fixed across subjects. As the choice condition followed the cue condition at a fixed delay
for each trial, “null” trials were included in each run (5 trials per run); in these trials, the
instruction cue appeared and no options followed. Subjects saw each of the 120 possible choices
two or three times, although not necessarily in the same trial type context. All choices made
in the task were based on hypothetical rewards, although subjects were instructed to choose as
if they would actually receive their choices.
2.3. Analysis of behavioral data
Single factor between-group comparisons were made via unpaired t-tests. Within group
comparisons of condition were made via paired t-tests. All t-tests were 2-tailed and were
conducted using Excel or SPSS. Multi-factorial comparisons were made using mixed repeated-
measures ANOVA in SPSS, with group as a between subjects factor. Where sphericity
assumptions were violated, a Greenhouse-Geisser non-sphericity correction was applied. For
each subject, we calculated an impulsive choice ratio (ICR), which is the proportion of Now
choices relative to all W condition choices made. Reward preference in DW trials was inferred
to be the unselected option. From these DW responses, we calculated an inferred ICR (iICR)
for each delay time and took the sum of |ICR – iICR| across all delays as a gross index of motor
error. To ensure the validity of parametric statistical tests, we used an arcsine-root
transformation of ICR data prior to statistical comparisons.
2.4. Imaging
T2*-weighted images (EPI) were acquired on a 4T Varian Inova whole body magnetic
resonance scanner (Palo Alto, CA) equipped with a TEM send-receive radio frequency (RF)
head coil, using a 1-shot gradient echo EPI sequence (TR = 2200 ms, TE = 28 ms, flip angle
= 20°) to detect blood oxygen level dependent (BOLD) contrast. The sequence employed phase
map correction to reduce Nyquist ghosts. To facilitate coverage of the ventral/orbital PFC,
sampling of k-space was in the order positive to negative (De Panfilis and Schwarzbauer,
2005). 40 coronal slices (3.5mm thick w/0.5mm gap) per volume were obtained (FOV =
22.4×22.4, in-plane resolution = 3.5mm). Each fMRI acquisition was preceded by 22s of
dummy gradient RF pulses to achieve steady-state tissue magnetization and minimize startle-
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induced motion. Low-resolution T1-weighted co-planar images were acquired for each
participant. In addition, a magnetization-prepared fast low-angle shot high-resolution
(MPFLASH) T1-weighted image was acquired for the purposes of normalizing data to
standardized space. E-Prime software (PST, Inc., Pittsburg, PA) synchronized the stimulus
display with the fMRI acquisition and collected subject responses via an MRI-compatible
keypad. An LCD projector (Epson, Long Beach, CA) projected stimuli onto a rear projection
screen (Stewart, Torrance, CA), which the subjects viewed via a mirror mounted within the
head coil.
2.5. Image Analysis
fMRI data were processed offline with a combination of in-house software, SPM2 (Wellcome
Dept. of Imaging Neuroscience, London, UK), and the Artifact Detection Tools package
(http://web.mit.edu/swg/software.htm). Images were first reconstructed into Cartesian space,
and sinc interpolated in time to correct for timing differences in slice acquisition. Data were
next motion corrected using a six-parameter, rigid-body, least-squares algorithm (Friston et
al., 1995), realigning all volumes to the first EPI volume, then smoothed with a 7 mm full-
width half-maximum (FWHM) Gaussian smoothing kernel. Each subject’s coplanar and
MPFLASH anatomical images were co-registered to the first EPI volume, and then normalized
to Montreal Neurological Institute (MNI) space and resampled to 2 mm3 isotropic voxels. The
functional data were analyzed in an event-related manner based on the modified general linear
model as implemented in the statistical package SPM2. Each subject’s model included a design
matrix of regressors of interest, which were δ functions positioned at the onset time of each
experimental event type (ready; instruction cue; choice pair) convolved with a canonical
hemodynamic response function (HRF). Noise spikes were rarely detected in the data
(ArtRepair2 Toolbox); these were modeled as covariates of no interest with duration of 2.2 s
and were not convolved with an HRF. Data were high-pass filtered using a cut-off of 128 s,
and serial autocorrelations were corrected with a restricted maximum likelihood algorithm
using a second-order autoregressive model (AR2 + white noise).
For each subject, linear contrast images were calculated from the regressor parameter estimates;
contrast images were then normalized into MNI space using the parameters derived from the
co-registered MPFLASH. Contrast maps were smoothed resulting in a total smoothing kernal
of 10mm FWHM. To test whether Naltrexone (NTX) would alter brain activity during
subjective decision-making, we compared the mean contrast values of (WANT – CON) from
the NTX and placebo (PBO) sessions within predefined regions of interest (ROI) from both
NTX and PBO sessions. ROI were 10mm3 spheres centered on coordinates identified in a
previous study (Boettiger et al., 2007). We also subtracted NTX and PBO session contrasts to
assess mapwise drug effects; the subtracted contrasts were then subject to both simple
regression and one-sample t-test analyses, as implemented in the SnPM3 analysis package
(http://www.sph.umich.edu/ni-stat/SnPM/). To control for multiple comparisons, statistical
non-parametric maps are corrected for Type I error (α < 0.001; whole brain volume),
determined by random permutation of the NTX-PBO subjective decision-making contrast
parameter estimates (with either ICR change or subject) in 5000 new analyses (Nichols and
Hayasaka, 2003; Nichols and Holmes, 2002). Activation peaks were localized within defined
anatomical regions, identified from the T1-weighted anatomical images obtained from each
subject, with reference to standard brain atlases (Duvernoy et al., 1991; Schmahmann et al.,
1999; Tzourio-Mazoyer et al., 2002).
2.6. Genetic Analysis
DNA extraction and analysis was conducted according to standard methods on samples
obtained from subjects providing informed consent. The Ernest Gallo Clinic and Research
Center Genomics Core carried out genotyping of the following polymorphisms with
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polymerase chain reaction using TaqMan® technology (Applied Biosystems): adrenergic
alpha-2A-receptor (ADRA2A; rs1800544), ankyrin repeat and kinase domain containing 1
(ANKK1/DRD2 Taq I; rs1800497), brain-derived neurotrophic factor (BDNF; rs6265),
cathechol-O-methyltransferase (COMT; rs4680), dopamine D2 receptor (DRD2; rs6277),
dopamine D4 receptor (DRD4; rs1800955), kappa-opioid receptor (OPRK1; rs1051660), mu-
opioid receptor (OPRM1; rs1799971), and tryptophan hydroxylase 1 (TPH1; rs1800532).
To estimate which genotypes had the greatest predictive value for the NTX effects on ICR and
ROI activity, linear multiple regression analyses were carried out using SPSS. For each
multiple regression analysis, we entered genotypes stepwise, divided into five blocks. The
blocks were as follows: block 1 – OPRM1; block 2 – OPRK1; block 3 – COMT, DRD2 TaqI,
DRD2_7a, DRD4; block 4 – ADRA2, TPH1; block 5 – BDNF.
3. Results
3.1. Sample Characteristics
The AA and CS groups were matched in terms of demographic variables. Specifically, the
groups did not differ in terms of education level, age, SES, IQ, gender composition, or ethnic
composition (Table 1). However, as expected, the AA subjects reported significantly higher
levels of alcohol abuse and alcohol-related problems (Table 1). A family history of alcohol
abuse was also more common among the AA group (Table 1).
3.2. NTX effects on behavior
Replicating our previous finding (Mitchell et al., 2007), a mixed design repeated measures
ANOVA found no significant main effect of drug (F1,17=1.07, p=0.341) or group (F1,17=0.01,
p=0.941) on RTs, although, as expected, we did observe a significant effect of trial type
(F1,24=49.1, p<0.001) (Table 2). This latter effect reflected increasing RTs from the CON to
WANT to DW trial types. We also found no significant drug × group interaction effect on RT
(F1,17=2.14, p=0.161).
A mixed design repeated measures ANOVA considering Impulsive Choice Ratio (ICR) as the
dependent variable found a significant main effect of group (F1,17=10.11, p<0.001), but not of
NTX (F1,17=1.22, p=0.286) on ICR. Replicating our previous results (Boettiger et al., 2007;
Mitchell et al., 2005b; Mitchell et al., 2007), the group effect was due to significantly higher
ICRs among the AA group relative to the CS group. We also found no significant drug × group
interaction effect on ICR (F1,17=0.48, p=0.496).
3.3. NTX effects on brain activity during subjective preference decisions
In a previous fMRI study, we found that during decisions between small, immediate (“Now”)
versus larger, delayed (“Later”) rewards the magnitude of the fMRI BOLD signal scales with
individual immediate reward bias in several brain areas (Boettiger et al., 2007). Here we first
tested whether acute NTX administration alters brain activity during subjective decision-
making in these areas. We then conducted an exploratory analysis to identify other areas in the
brain in which activity during decision-making is significantly altered. Finally, across the
whole brain, we tested for correlations between NTX’s effect on brain activity during Now
versus Later decision-making and its effect on choice behavior.
3.3.1. Effects within choice-predicting ROI—For the Region of interest (ROI) analyses,
we defined the ROIs as 10 mm3 spheres centered on the coordinates identified in our previous
study (Boettiger et al., 2007). These areas each predict individual immediate reward selection
bias during Now versus Later decision-making. These areas can be divided according to those
in which activity during such decisions is directly correlated with Now bias (“Now areas”) and
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one in which activity during such decisions is inversely correlated with Now bias (“Later”
area). For each ROI, the mean parameter estimates (β values) for a subjective decision-making
contrast (WANT-CON) were extracted from both the NTX and the placebo sessions and then
subject to further statistical analyses.
3.3.1.1. “Now” Areas: To test for significant effects of NTX on BOLD activity during
decision-making in Now ROIs, we conducted paired t-tests with ROI β values as dependent
variables. For the three ROIs that were the focus of our previous study (posterior parietal cortex,
superior frontal gyrus, and parahippocampal gyrus), we did not observe a significant effect of
NTX on brain activity subjective decision-making (t18, minimum p value = 0.548). We
observed similar effects in additional areas in the temporal lobe and cerebellum (see Table 3),
in which activity during Now versus Later decisions is also known to correlate with Now bias
(t18, minimum p value = 0.489). These results indicate that any effect that NTX may have on
temporal discounting behavior are not mediated by actions in any of these brain areas.
3.3.1.2. “Later” Area: We next tested for a significant effect of NTX on BOLD activity during
decision-making in the Later ROI in the OFC, again using a paired t -test with ROI β values
as dependent variables. Here we observed that during NTX sessions, brain activity during
subjective decision-making was significantly elevated (Figure 2; t18, p = 0.045). Together with
our previous finding that activity in the OFC during Now versus Later decisions inversely
correlates with Now bias, this result suggests that NTX may reduce impulsive decision-making
via effects on the OFC.
3.3.1.3. Group interaction with NTX effects on ROI: Two-way factorial ANOVA with ROI
β values as dependent variables failed to identify a significant group β drug interaction for any
of the Now or Later ROIs (maximum F1,17 = 1.44, p = 0.256). These findings suggest that NTX
does not exert differential brain effects based on alcohol use history in areas that predict
Now versus Later bias.
3.3.1.4. Genotype interaction with NTX effects: 3.3.1.4.1. Effects on choice behavior:
Multiple linear regression analysis was used to determine whether any of the SNPs we assayed
had significant predictive value in terms of the NTX effect on ICR. We found that a single
SNP had significant predictive power: the Val66Met locus of BDNF (r=0.52, t15=−2.27,
p=0.04). That is, electing Now more often during the NTX session was associated with fewer
Val alleles at position 66 in the BDNF protein. No other genotype factor added into the model
added significantly more predictive power than BDNF genotype alone for the NTX effect on
ICR. A two-way factorial ANOVA with ICR as dependent variable confirmed a significant
interaction between drug condition and BDNF genotype (F1,13 = 3.99, p = 0.045; Figure 3).
There was no significant main effect of BDNF genotype on choice behavior (p > 0.8).
3.3.1.4.2. Effects on brain activity during subjective choice: We performed an identical
multiple linear regression analysis using the OFC ROI β values as the dependent variable to
test whether any of the tested genotypes held significant predictive value for NTX’s effect.
This procedure found that none of the SNPs tested significantly predicted the NTX effect on
OFC activity during Now versus Later choices.
3.3.2. Mapwise analysis of NTX effects
3.3.2.1. Sites in which NTX raised or lowered activity: In addition to our ROI-based
analyses, we conducted an exploratory mapwise analysis of NTX’s effect on BOLD signal
during subjective decision-making. We found that NTX elevated activity during Now versus
Later decisions in the left OFC, the left inferotemporal cortex, and bilateral sites in the
cerebellum (Figure 4A). In addition, we found that NTX depressed activity during Now versus
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Later decision-making in the right superior temporal gyrus (Figure 4B). See Table 4 for peak
coordinates.
3.3.2.2. Correlation between NTX effects on brain and on behavior: Our final analysis
employed simple regression analysis to identify brain areas in which NTX’s effects on
decision-making activity predicted NTX’s effect on behavior. To accomplish this, we entered
the choice condition drug contrasts (NTX – PBO) from each subject into a map-wise simple
regression analysis. This correlation analysis exploited the intersubject variability in NTX
behavioral effects to identify differences in NTX effects on the BOLD signal during Now versus
Later choices. Using the ICR change of each subject as a between subjects statistical regressor,
we found a significant positive correlation between ICR change and session difference in
activity between during preference-based decision-making in a constellation of areas (Table
5). Notably, one such site was in the right lateral OFC (Figure 5A, Table 5), falling within the
OFC ROI investigated above. As can be seen in the regression plot of Figure 5B, the NTX
effect on OFC activity during Now versus Later decisions was inversely correlated with the
NTX effect on ICR. In other words, elevated OFC activity on NTX was associated with an
increased the likelihood of selecting the larger, delayed reward (Figure 5B).
6. Discussion
6.1. NTX modulation of OFC function
Determining the functional effects of NTX on the human brain is an important step in
understanding the bases for variability in its efficacy. This information may not only help
predict whether an individual will respond to NTX, it may also help identify which of NTX’s
actions are critical to its therapeutic effect. This latter information may prove especially
valuable in driving the development of new treatments for alcoholism and related disorders,
as it could suggest which brain regions are critical therapeutic targets and thus help guide or
validate animal experiments. To date, this study is only the second published report about the
effects of NTX in the brains of people with a history of alcohol dependence. Here we found
that among areas that predict individual bias towards immediate rewards, a single area was
modulated by NTX during decision-making: the OFC. Interestingly, the other recent study
found that NTX modulates OFC responses to alcohol cues in alcohol dependent subjects
(Myrick et al., 2008). Together these findings highlight the OFC as a key brain area affected
by NTX.
The OFC is thought to play a critical role in moderating impulsive choice (Mobini et al.,
2002; Rudebeck et al., 2006), and in representing subjective value during choice tasks
(Izquierdo et al., 2004; Padoa-Schioppa and Assad, 2006; Roesch and Olson, 2004;
Schoenbaum and Roesch, 2005). OFC damage impairs the ability of animals to change their
responses to stimuli that are no longer reinforced (Dias et al., 1996; McAlonan and Brown,
2003; Mishkin, 1964; Ostlund and Balleine, 2007; Schoenbaum and Roesch, 2005;
Schoenbaum et al., 2007; Tait and Brown, 2007). Likewise, patients with damage to the OFC,
due either to focal lesions (Rolls et al., 1994) or to degenerative frontotemporal dementia
(Rahman et al., 1999), also show impairment in changing their responses when the “rules” for
correct responding change. Human neuroimaging studies also support a role for the OFC in
overcoming learned response contingencies (Boettiger CA, 2004; Cools et al., 2002; Elliott et
al., 2000; O’Doherty et al., 2004; Remijnse et al., 2006).
Such inability to refrain from previously preferred actions in response to formerly rewarding
cues that are no longer reinforced is highly reminiscent of the transition from flexible to habitual
responding that is characteristic of drug addiction. It should come as no surprise then, that
neuroimaging studies have repeatedly found abnormal OFC functioning in substance abusers
(Boettiger et al., 2007; Dom et al., 2005; Ersche et al., 2005; London et al., 2000; Volkow and
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Fowler, 2000). The present data suggest that NTX may support the long-term decision-making
critical to recovery from alcoholism by increasing activity in the OFC. Determining whether
this biomarker is an addiction vulnerability or relapse risk factor is an important future question.
6.2. Immediate reward bias and endogenous opioids
These data are consistent with our previous finding that blockade of endogenous opioids with
NTX can alter immediate reward bias and that this effect is highly variable across individuals
(Mitchell et al., 2007). The present results provide new data regarding possible neurobiological
sources for this variability. First, we found that a common polymorphism in the BDNF gene
predicted individual NTX effect on immediate reward bias. Second, we identified brain regions
in which the difference in activity during Now versus Later decisions between NTX and
placebo sessions predicted changes in choice behavior. These areas included the right lateral
OFC, an area in which high activity during Now versus Later decisions predicts Later reward
selection bias. Consistent with this finding, here we show an association of NTX elevated OFC
activity with reduced selection of immediate rewards. The two primary targets of NTX, mu-
opioid receptors and kappa-opioid receptors, are both expressed at high levels in the OFC
(Gorelick et al., 2005; Staley et al., 1997; Zubieta et al., 1999; Zubieta et al., 1996), thus NTX
may be directly mediating its effects on OFC activity via local receptors. However, many of
the OFC’s inputs, including the dorsal prefrontal cortex, temporal cortex, the amygdala, and
the VTA, also show rich expression of opioid receptors (Gorelick et al., 2005; Maurer et al.,
1983; Staley et al., 1997; Zubieta et al., 1999; Zubieta et al., 1996), thus NTX’s effect on OFC
activity may alternatively be mediated indirectly through one or more of these areas. For
example, opioid agonists directly inhibit cortically projecting VTA dopamine neurons in rats
(Margolis et al., 2006), thus NTX’s actions at opioid receptors in the VTA could increase
dopaminergic input to the OFC, resulting in the heightened OFC activity during decision-
making that we observed. However, we do not currently know how endogenous opioids that
affect the release of DA alter the BOLD signal in the human OFC. Rat studies indicate that
whereas μ-opioids in the VTA increase cortical and striatal DA, κ-opioids inhibit striatal
dopamine, since NTX blocks both receptors, its effect on cortical DA levels is uncertain (Herz,
1995; Margolis et al., 2006; Spanagel et al., 1992) and could depend on the relative level of
μ-versus κ-mediated actions. Relative μ-versus κ-effects would be expected to differ in subjects
with low circulating levels of endogenous μ-receptor ligands, such as alcoholics and their off-
spring (Dai et al., 2005; del Arbol et al., 1995; Govoni et al., 1983; Vescovi et al., 1992), or in
those with low levels of μ-receptor expression, as is found in subjects with low frontal DA
levels due to their COMT genotype (Berthele et al., 2005), and in subjects with the A118G
polymorphism of the μ-opioid receptor (Zhang et al., 2005). Combining PET imaging of NTX
binding with behavioral studies of immediate reward bias shifts may shed light on this issue.
Clinical and pre-clinical data support the hypothesis that opioids regulate immediate reward
bias. In rats, NTX reverses morphine induced immediate reward bias (Kieres et al., 2004). In
humans, NTX shifts preference from immediate alcohol reward to delayed monetary reward
in a lab bar setting (O’Malley et al., 2002). Moreover, NTX attenuates a variety of impulsive
behaviors, including pathological gambling (Kim et al., 2001), binge eating in bulimics
(Marrazzi et al., 1995), compulsive sexual behavior (Raymond et al., 2002), self-injurious
behavior (Symons et al., 2004), and kleptomania (Grant, 2005). Together these results suggest
that opioids promote impulsivity, and that opioid receptor blockade via NTX may improve
self-control. The fact that immediate reward bias is reduced by acute elevation of DA levels
(de Wit et al., 2002; Wade et al., 2000), further suggests that NTX may alter immediate reward
bias via indirect effects on DA release, an idea consistent with studies demonstrating opioid
regulation of dopamine neurons (Berthele et al., 2005; Margolis et al., 2006; Ostrowski et al.,
1982; Sesack and Pickel, 1992).
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6.3. BDNF and the endogenous opioid system
The Met allele of the BDNF Val66Met polymorphism is associated with reduced activity-
dependent release of BDNF, impaired episodic memory, and reduced Hippocampal function
(Egan et al., 2003). It has also been associated with increased anxiety (Chen et al., 2006),
increased risk of eating disorders and schizophrenia, and reduced risk of substance abuse
disorders (Gratacos et al., 2008). Although endogenous opioids are known to regulate BDNF
expression (Zhang et al., 2007; Zhang et al., 2006), it remains unclear how variation in the
BDNF system could alter response to endogenous opioid blockade. One recent study however
indicates that genetic variability in the BDNF gene alters response to methadone treatment in
opioid addicts (de Cid et al., 2008), providing some precedence for variability in opioid system
responses based on BNDF genotype.
6.4. Limitations
6.4.1. Sample size—One limitation of the results reported here is the small sample size.
This limitation is particularly critical for interpreting the genetic association data. Thus, the
finding that BDNF genotype predicts NTX effects on impulsive decision-making should be
considered as pilot data, which await confirmation in a larger scale study. It is also critical to
acknowledge that our small sample size may have resulted in false negatives with regard to
the moderating effects of the other SNPs tested.
6.4.2. Acute dose of NTX—A second limitation of the present study is the use of a single
acute dose of NTX. Typical therapeutic use of NTX entails daily dosing, which may result in
rather different responses to the drug. However, clinical data demonstrate equivalent or greater
efficacy of acute NTX dosing, relative to daily maintenance, in reducing excessive alcohol
intake (Hernandez-Avila et al., 2006).
6.4.3. No clinical outcome measures—A final limitation of the present study is the lack
of any clinical outcome measures. Thus, we are unable to say whether the NTX effects on
decision-making behavior or on brain activity during decision-making are directly correlated
with NTX’s therapeutic effects. Future studies that incorporate this decision-making task into
a clinical trial would shed light on this issue.
6.5. Summary
The present findings identify actions of NTX in the human brain that may contribute to its
therapeutic effect in the treatment of alcoholism. Moreover, OFC activity during subjective
decisions may be a key therapeutic target for alcoholism medication development. Individual
differences in NTX effects on the OFC may contribute to the variable clinical efficacy of NTX.
Individual differences in BDNF genotype may also contribute to the variability in NTX’s
effects on behavior.
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Figure 1. Illustration of behavioral paradigm
The temporal sequence of events is depicted for an example WANT trial. Illumination of a
fixation cross (“Ready”) indicated the start of each trial. The instruction cue (in this case
“WANT”) was then displayed for 4.4 s, informing the subject as to the upcoming trial type.
The two options (Now and Later) then appeared while the instruction cue remained on the
screen. The specific dollar amounts (from $1 to $100) and the time of availability (from
“Today” to “6 months” later) varied across trials, as did the differences between the two options.
The options remained on the screen for 4.4 s, although subjects had 6.6 s to indicate their choice.
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Figure 2. NTX significantly elevates activity during decision-making in the OFC
Plot of the mean Now vs. Later subjective decision-making parameter estimates for the OFC
ROI as a function of drug condition. Plots reflect mean ± S.D. NTX, naltrexone; PBO, placebo.
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Figure 3. Genotype at the BDNF 66 locus predicts NTX effect on ICR
Ratio of impulsive choices as a function of genotype and drug condition. There was a significant
interaction effect between drug condition and genotype at the BDNF 66 locus on impulsive
choice probability. The 66Met/Met genotype was associated with greater Now bias on NTX.
Met/Met, 66Met/Met; Val/Met, 66Val/Met; Val/Val, 66Val/Val; BDNF, brain derived neurotrophic
factor.
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Figure 4. Mapwise analyses of NTX effects
Statistical non-parametric t-maps contrasting [WANT-CON] activity in NTX and placebo
sessions, overlaid on a standard T1-weighted anatomical image. Criterion threshold was based
on permutation-based voxelwise correction of FWE (p < 0.001), with a minimum cluster size
of 5 contiguous voxels. A) Areas more active during subjective decision-making on NTX. B)
The indicated area in the superior temporal gyrus was less active during subjective decision-
making on NTX. Cr1, cerebellum crus 1; Cr2, cerebellum crus 2; 7b, cerebellum lobule 7b;
IT, inferotemporal cortex; OFC, orbitofrontal cortex; STG, superior temporal gyrus.
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Figure 5. NTX effect on the OFC predicts NTX effect on choice behavior
Statistical non-parametric t -maps depicting results of a mapwise simple regression analysis.
A) A site in the OFC is shown in which NTX’s effect on activity during decision-making
significantly correlated with NTX’s effect on choice behavior. B) Plot of each subject’s NTX
session change in Now vs. Later subjective decision-making parameter estimate as a function
of change in ICR for the peak of the region displayed in B; peak regression statistic displayed
in plot. Units are in standard deviations, mean = 0.
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Table 1
Subject demographics
Values are reported as mean ± standard deviation. Reported p-values reflect the results of unpaired two-tailed
comparison between groups.
Participants AA (n = 9) CS (n=10) t17 p value
General
Age (yrs) 30 ± 8 27 ± 3 1.49 ns
Education (Hollingshead subscore) 6 ± 1 6 ± 1 1.77 ns
Hollingshead SES 51 ± 9 50 ± 2 0.34 ns
Shipley Institute of Living Scale (raw) 65 ± 8 72 ± 8 1.70 ns
Gender (# female) 5 3 ns†
Ethnicity (# non-white) 2 1 ns†
Alcohol-related
AUDIT 19 ± 7 5 ± 2 6.30 < 0.001
DUSI-I (%) 75 ± 15 13 ± 18 8.06 < 0.001
FTQ (#) 3 ± 2 1 ± 1 2.99 < 0.01
AA, Abstinent alcoholic; CS, Control subject; SES, socioeconomic status; AUDIT, Alcohol Use Disorders Identification Test; DUSI-I, Drug Use Screening
Inventory, Domain I; FTQ, Family Tree Questionnaire;
†
p-value represents results of χ2 test.
ns: p > 0.05
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Table 2
NTX effects on behavior
Changes in reaction times and ICR in the delay discounting task following 50mg naltrexone (NTX), relative to the
placebo session.
Participants AA (n = 9) CS (n=10) All (n=19)
Reaction Times Changes (%)
CON −6 ± 9 8 ± 10 1 ± 12
W −5 ± 15 3 ± 14 −1 ± 15
DW −4 ± 16 3 ± 17 0 ± 16
ICR Changes (%) 5 ± 14 3 ± 14 4 ± 14
AA, Abstinent alcoholic; CS, Control subject; W, WANT trials; DW, DON’T WANT trials; CON, Control trials (SOONER & LARGER); ICR, Impulsive
choice ratio. All data given as mean ± standard deviation.
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Table 3
Peak coordinates for ROI analyses
ROI anatomical region, hemisphere, and coordinates of ROI center based on the Montreal Neurological Institute (MNI)
coordinate system value are given.
Brain region Hemisphere MNI coordinates [x, y, z] (mm)
Now ROI centers
Supramarginal gyrus (parietal lobe) Right 66, −42, 44
Cerebellum, posterior lobe (lobule VIII) Right 36, −52, −62
Middle temporal gyrus Right 56, −52, −2
Inferior temporal gyrus Right 68, −50, −12
Parahippocampal gyrus (Gyrus ambiens, Entorhinal area,
Semilunar gyrus)
Right 18, −4, −28
Superior frontal gyrus Left −22, 50, 44
Later ROI center
Lateral orbital gyrus Right 58, 36, −10
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Table 4
Peak coordinates for sites of activity modulation by NTX
Anatomical region, hemisphere, and peak coordinates based on the Montreal Neurological Institute (MNI) coordinate
system value are given.
Brain region Hemisphere MNI coordinates [x, y, z] (mm)
NTX increased activity during decision-making
Lateral orbital gyrus Left −40, 46, −11
Inferior temporal gyrus Left −37, 0, −41
Cerebellum, crus I Left −37, −42, −35
Cerebellum, lobule VIIb Left −44, −42, −49
Cerebellum, crus I Right 45, −46, −35
Cerebellum, crus II Left −20, −76, −45
NTX decreased activity during decision-making
Superior temporal gyrus Right 63, 10, −8
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Table 5
Peak coordinates for sites in which NTX co-modulated BOLD and ICR
Anatomical region, hemisphere, and peak coordinates based on the Montreal Neurological Institute (MNI) coordinate
system value are given.
Brain region Hemisphere MNI coordinates [x, y, z] (mm)
NTX BOLD effect inversely related to ICR effect
Middle frontal gyrus Right 40, 46, 6
Lateral orbital gyrus Right 51, 38, −16
Superior temporal pole Left −47, 12, −14
Middle temporal pole Left −27, 9, −37
Inferior frontal junction Right 45, 8, 28
Inferior temporal gyrus Right 50, 4, −38
Middle temporal gyrus Left −54, 2, −22
Supplementary motor area Right 15, 1, 72
Cerebellum, lobule VI Right 36, −43, −32
Right 32, −64, −21
NTX BOLD effect directly related to ICR effect
Middle orbital gyrus Left −20, 57, −14
Inferior temporal gyrus Left −59, −9, −29
Middle temporal gyrus Left −68, −38, 5
Intraparietal sulcus Left −44, −45, 61
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